Bio-Thera Solutions, Ltd. — Investor Relations & Filings
About Bio-Thera Solutions, Ltd.
Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 百奥泰 2023年度募集资金存放与使用情况报告的鉴证报告 | 2024-03-28 | Chinese | |
| 百奥泰 第二届董事会第十四次会议决议的公告 | 2024-03-28 | Chinese | |
| 百奥泰 2023年度独立董事述职报告（汪建平） | 2024-03-28 | Chinese | |
| 百奥泰 2023年度非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告 | 2024-03-28 | Chinese | |
| 百奥泰 关于续聘会计师事务所的公告 | 2024-03-28 | Chinese | |
| 中国国际金融股份有限公司关于百奥泰生物制药股份有限公司2024年度日常关联交易预计的核查意见 | 2024-03-28 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
15 filings
| |||||
| 39228599 | 百奥泰 2023年度募集资金存放与使用情况报告的鉴证报告 | 2024-03-28 | Chinese | ||
| 39228517 | 百奥泰 第二届董事会第十四次会议决议的公告 | 2024-03-28 | Chinese | ||
| 39228504 | 百奥泰 2023年度独立董事述职报告（汪建平） | 2024-03-28 | Chinese | ||
| 39228497 | 百奥泰 2023年度非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告 | 2024-03-28 | Chinese | ||
| 39228476 | 百奥泰 关于续聘会计师事务所的公告 | 2024-03-28 | Chinese | ||
| 39228471 | 中国国际金融股份有限公司关于百奥泰生物制药股份有限公司2024年度日常关联交易预计的核查意见 | 2024-03-28 | Chinese | ||
| 39228464 | 百奥泰 关于公司2024年度董事、监事和高级管理人员薪酬方案的公告 | 2024-03-28 | Chinese | ||
| 39228454 | 百奥泰 2023年年度报告 | 2024-03-28 | Chinese | ||
| 39228392 | 百奥泰 审计委员会对会计师事务所2023年度履行监督职责情况的报告 | 2024-03-28 | Chinese | ||
| 39228384 | 百奥泰 董事会关于独立董事独立性情况的专项意见 | 2024-03-28 | Chinese | ||
| 39228371 | 百奥泰 第二届董事会独立董事第一次专门会议决议 | 2024-03-28 | Chinese | ||
| 39228359 | 百奥泰 与关联方签署分布式屋顶光伏电站能源管理协议暨关联交易的公告 | 2024-03-28 | Chinese | ||
| 39228346 | 百奥泰 2023年度会计师事务所履职情况评估报告 | 2024-03-28 | Chinese | ||
| 39228342 | 百奥泰 2023年年度报告摘要 | 2024-03-28 | Chinese | ||
| 39228315 | 中国国际金融股份有限公司关于百奥泰生物制药股份有限公司使用部分暂时闲置募集资金及部分自有资金进行现金管理的核查意见 | 2024-03-28 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Bio-Thera Solutions, Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58210/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58210 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58210 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58210 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58210}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bio-Thera Solutions, Ltd. (id: 58210)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.